MDGL — Madrigal Pharmaceuticals, Inc.

Summary of Madrigal Pharmaceuticals Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Sales: Q1 2026 net sales reached $311.3 million, a 127% increase year-over-year, contributing to a trailing 12-month total of over $1.1 billion.
• Active Patients: The number of active patients on Rezdiffra increased to over 42,250, representing a 2.5x growth compared to Q1 2025.
• Operating Expenses: Total operating expenses included $34 million in non-cash stock-based compensation. R&D expenses were $108.7 million, up from $44.2 million year-over-year, primarily due to one-time business development costs.
• Net Loss: The net loss for Q1 2026 was $94.4 million, compared to $73.2 million in the prior year, influenced by upfront business development expenses.
• Cash Position: Cash, cash equivalents, and marketable securities totaled $817.9 million at the end of Q1 2026.

2. Strategic Updates and Business Highlights

• Rezdiffra Performance: The drug has achieved blockbuster status with significant market penetration potential, as the MASH (Metabolic Associated Steatotic Liver Disease) market is still in its early stages.
• Pipeline Expansion: Madrigal has added a new siRNA asset targeting the PNPLA3 gene, enhancing its pipeline to over 10 programs aimed at extending leadership in MASH.
• Market Dynamics: The U.S. addressable market for MASH has expanded nearly 50% since 2023, with ongoing efforts to increase diagnosis rates and patient treatment.

3. Forward Guidance and Outlook

• Patient Growth: The company expects to continue adding patients steadily throughout 2026, with Q2 showing strong momentum.
• Sales Growth: Anticipated gross-to-net discounts are expected to remain in the mid- to high 30s for the remainder of 2026.
• Profitability: While profitability is not expected in 2026, the company is preparing for future profitability based on its strong market position and pipeline.

4. Bad News, Challenges, or Points of Concern

• Increased Expenses: Significant increases in R&D and SG&A expenses are anticipated, particularly due to ongoing investments in commercial activities and business development.
• Net Loss: The continued net loss raises concerns about the sustainability of operations without achieving profitability in the near term.
• Market Competition: Although competition is driving market growth, it may also present challenges in maintaining Rezdiffra's market share as new therapies enter the space.

5. Notable Q&A Insights

• Q2 Trends: Management indicated strong trends in Q2, with expectations of continued patient growth despite a typical Q1 effect observed in new patient additions.
• Prescriber Dynamics: The majority of prescriptions are currently from gastroenterologists, with expectations for endocrinologists to become a more significant source as awareness grows.
• Combination Therapies: Approximately 25% of patients are on a combination therapy with GLP-1s, and management anticipates this will increase as more patients are treated.
• Pipeline Strategy: The company remains open to further business development opportunities, focusing on mechanistically complementary therapies to enhance Rezdiffra's efficacy.

This summary encapsulates the key points from Madrigal Pharmaceuticals' Q1 2026 earnings call, highlighting both the positive developments and the challenges ahead.